4-1BB/4-1BBL signaling pathway in patients with influenza A (H1N1) virus-associated pneumonia
https://doi.org/10.23946/2500-0764-2022-7-1-64-69
Abstract
Aim. To evaluate the activity of the 4-1BB/4-1BBL signaling pathway in patients with influenza A (H1N1) virus-associated pneumonia.
Materials and Methods. Here we enrolled 85 patients (41 males and 44 females, median age 48 (36-62) years) with influenza A (H1N1) virus-associated pneumonia. Among the exclusion criteria were unstable hemodynamics, BMI > 30, diabetes mellitus, HIV, tuberculosis, and cancer. Control group consisted of 15 healthy donors. The diagnosis of influenza A / H1N1 was confirmed by a positive PCR test. Pneumonia was diagnosed according to the Federal Clinical Guidelines «Community-acquired pneumonia in adults». Severity of pneumonia was evaluated by using CURB-65 and SMART-COP scales as well as IDSA/ATS criteria. Plasma concentration of 4-1BB (CD137 or TNFRSF9, an inducible costimulatory receptor expressed on activated T cells and antigen-presenting cells) was determined by flow cytometry.
Results. Patients with moderate and severe influenza A (H1N1) virus-associated pneumonia had 1.5- and 2.4 fold-increased concentration of plasma 4-1ВВ as compared with the healthy controls.
Conclusion. The 4-1BB/4-1BBL signaling pathway, involved in multiple immune reactions, is associated with the severity of influenza A (H1N1) virus-associated pneumonia.
Keywords
Supporting agencies: The study was financially supported by Chita State Medical Academy (Russian Federation).
About the Authors
A. V. Malyarchikov
Chita State Medical Academy
Russian Federation
Russian Federation
Andrey V. Malyarchikov, MD, PhD, Head of Simulation Training
Department
39a, Gor’kogo Street, Chita, 672000
K. G. Shаpovаlov
Chita State Medical Academy
Russian Federation
Russian Federation
Konstantin G. Shapovalov, MD, DSc, Professor, Head of the
Department of Anesthesiology, Resuscitation and Critical Care Medicine
39a, Gor’kogo Street, Chita, 672000
References
1. Crimi E, Cirri S, Benincasa G, Napoli C. Epigenetics Mecha-nisms in Multiorgan Dysfunction Syndrome. Anesth Analg. 2019;129(5):1422-1432. https://doi.org/10.1213/ANE.0000000000004331
2. Bomsztyk K, Mar D, An D, Sharifian R, Mikula M, Gharib SA, Altemeier WA, Liles WC, Denisenko O. Experimental acute lung injury in-duces multi-organ epigenetic modifications in key angiogenic genes impli-cated in sepsis-associated endothelial dysfunction. Crit Care. 2015;19(1):225. https://doi.org/10.1186/s13054-015-0943-4
3. Chereshnev VA, Gusev EYu. Immunological and pathophysio-logical mechanisms of systemic inflammation. Medical Immunology (Russia). 2012;14(1-2):9-20. (In Russ). https://doi.org/10.15789/1563-0625-2012-1-2-9-20
4. Rubtsov MS, Shukevich DL. Modern extracorporeal methods for critical conditions caused by systemic inflammatory response (review). Russian Journal of Anaesthesiology and Reanimatology. 2019;4:20-30. (In Russ).
5. Croft M, Duan W, Choi H, Eun SY, Madireddi S, Mehta A. TNF superfamily in inflammatory disease: translating basic insights. Trends Immunol. 2012;33(3):144-52. https://doi.org/10.1016/j.it.2011.10.004
6. Etxeberria I, Glez-Vaz J, Teijeira Á, Melero I. New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis. ESMO Open. 2020;4(Suppl 3):e000733. https://doi.org/10.1136/esmoopen-2020-000733
7. Vinay D, Kwon B. 4-1BB signaling beyond T cells. Cell Mol Immunol. 2011;8(4): 281-284 (2011). https://doi.org/10.1038/cmi.2010.82
8. Zapata JM, Perez-Chacon G, Carr-Baena P, Martinez-Forero I, Azpilikueta A, Otano I, Melero I. CD137 (4-1BB) Signalosome: Complexi-ty Is a Matter of TRAFs. Front Immunol. 2018;9:2618. https://doi.org/10.3389/fimmu.2018.02618
9. Lin GH, Sedgmen BJ, Moraes TJ, Snell LM, Topham DJ, Watts TH. Endogenous 4-1BB ligand plays a critical role in protection from influenza-induced disease. J Immunol. 2009;182(2):934-947. https://doi.org/10.4049/jimmunol.182.2.934
10. Bang BR, Kim SJ, Yagita H, Croft M, Kang YJ. Inhibition of 4-1BBLregulated TLR response in macrophages ameliorates endotoxininduced sepsis in mice. Eur J Immunol. 2015;45(3):886-892. https://doi.org/10.1002/eji.201445174
11. Romanova EN, Serebryakova OM, Govorin AV, Filev AP. P. Multiple organ dysfunction in patients with influenza H1N1/09 complicated by pneumonia. The Transbaikal medical bulletin. 2017;1: 107-116 (in Russ).
12. Safety of Remdesivir and Tocilizumab in COVID-19 Treat-ment. Safety and Risk of Pharmacotherapy. 2020;8(3):160-162. (In Russ). https://doi.org/10.30895/2312-7821-2020-8-3-160-162
13. Sanchez-Paulete AR, Labiano S, Rodriguez-Ruiz ME, Azpilikueta A, Etxeberria I, Bolaños E, Lang V, Rodriguez M, Aznar MA, Jure-Kunkel M, Melero I. Deciphering СD137 (4-1BB) signaling in T-cell costimulation for translation into suc-cessful cancer immunotherapy. Eur J Immunol. 2016;46(3):513-522. https://doi.org/10.1002/eji.201445388
14. Yuan W, Xu C, Li B, Xia H, Pan Y, Zhong W, Xu L, Chen R, Wang B. Contributions of Costimulatory Molecule CD137 in Endothelial Cells. J Am Heart Assoc. 2021;10(11):e020721. https://doi.org/10.1161/JAHA.120.020721
15. Jung IH, Oh GT. The roles of CD137 signaling in athero-sclerosis. Korean Circ J. 2016;46:753-761. https://doi.org/10.4070/kcj.2016.46.6.753
16. Jeon HJ, Choi JH, Jung IH, Park JG, Lee MR, Lee MN, Kim B, Yoo JY, Jeong SJ, Kim DY, Park JE, Park HY, Kwack K, Choi BK, Kwon BS, Oh GT. CD137 (4-1BB) defi-ciency reduces atherosclerosis in hyperlipidemic mice. Circula-tion. 2010;121(9):1124-1133. https://doi.org/10.1161/CIRCULATIONAHA.109.882704
17. Söderström LÅ, Tarnawski L, Olofsson PS. CD137: A checkpoint regulator involved in atherosclerosis. Atheroscle-rosis. 2018;272:66-72. https://doi.org/10.1016/j.atherosclerosis.2018.03.007
18. Xu L, Geng T, Zang G, Bo L, Liang Y, Zhou H, Yan J. Exosome derived from CD137-modified endothelial cells regu-lates the Th17 responses in atherosclerosis. J Cell Mol Med. 2020;24(8):4659-4667. https://doi.org/10.1111/jcmm.15130
19. Kwon B. Regulation of Inflammation by Bidirectional Signaling through CD137 and Its Ligand. Immune Netw. 2012;12(5):176-180. https://doi.org/10.4110/in.2012.12.5.176
Review
For citations:
Malyarchikov A.V., Shаpovаlov K.G. 4-1BB/4-1BBL signaling pathway in patients with influenza A (H1N1) virus-associated pneumonia. Fundamental and Clinical Medicine. 2022;7(1):64-69. (In Russ.) https://doi.org/10.23946/2500-0764-2022-7-1-64-69
Views:
313
Email this article 